Acer Therapeutics (ACER)
(Delayed Data from OTC)
$0.66 USD
0.00 (0.00%)
Updated Nov 20, 2023 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Acer Therapeutics Inc. [ACER]
Reports for Purchase
Showing records 21 - 40 ( 213 total )
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
ACER-801 Development to Include PTSD; ACER-001 Patent Allowance Received
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
ACER-001 PDUFA Date is Only Five Months Away; Reiterate Buy Rating and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
2Q22: All Eyes on a Highly Likely Positive PDUFA Date in January 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
ACER-001 NDA Accepted for Review with 1-15-23 PDUFA Date, MSUD IND Filed
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Refiles ACER-001 NDA, Expecting FDA Approval Within Six Months
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Looking for the ACER-001 NDA CRL to be Appropriately Addressed; Reiterate Buy and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
ACER-001 NDA Gets CRL, but Issues Are Minor, Projecting July Resubmission
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
1Q22: Eventful Rest of 2022 - ACER-001 PDUFA, EDSIVO Trial, ACER-801 Data
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Agrees with FDA on SPA for Phase 3 EDSIVO Trial in vEDS, Starts Late 2Q22
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Positive ACER-001 Data Ahead of June PDUFA Date; Reiterate Buy and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Two Posters at SIMD Highlight ACER-001: Solid BioEq, Better Taste-masking
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
EDSIVO Granted FDA Breakthrough Therapy Designation For Vascular Ehlers-Danlos Syndrome; Reiterate Buy and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
FDA Grants EDSIVO Breakthrough Therapy Designation for vEDS
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J